{
  "id": "63eef60ef36125a42600000c",
  "type": "factoid",
  "question": "Olokizumab is tested for which disease?",
  "ideal_answer": "Olokizumab, a monoclonal antibody against interleukin 6, improves outcomes of rheumatoid arthritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
    "http://www.ncbi.nlm.nih.gov/pubmed/36001712"
  ],
  "snippets": [
    {
      "text": "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34344706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "rheumatoid arthritis"
}